Literature DB >> 24112096

The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Suzanne Nielsen1, Maureen Hillhouse, Roger D Weiss, Larissa Mooney, Jennifer Sharpe Potter, Joshua Lee, Marc N Gourevitch, Walter Ling.   

Abstract

BACKGROUND AND OBJECTIVES: This analysis aims to: (1) compare induction experiences among participants who self-reported using one of the four most commonly reported POs, and (2) examine factors associated with difficult bup-nx induction. Our hypothesis, based on previous research and current guidelines, is that those on longer-acting opioids will have experienced more difficult inductions.
METHODS: The Prescription Opioid Addiction Treatment Study (POATS) was a multi-site, randomized clinical trial, using a two-phase adaptive treatment research design. This analysis examines bup-nx induction of participants who self-reported primary PO use of methadone, ER-oxycodone, IR-oxycodone, and hydrocodone (n = 69). Analyses examined characteristics associated with difficult induction, defined as increased withdrawal symptoms measured by the Clinical Opiate Withdrawal Scale (COWS) after the first bup-nx dose with higher scores denoting greater withdrawal symptoms/severity.
RESULTS: Contrary to our hypothesis, difficult induction experiences did not differ by primary PO type. Those who experienced a post-induction increase in COWS score had lower pre-dose COWS scores compared to those who did not experience a post-induction increase in COWS score (10.09 vs. 12.77, t(624) = -13.56, p < .001). Demographics characteristics, depression, and pain history did not predict a difficult induction. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Difficult bup-nx inductions were not associated with participants' primary PO. Severity of withdrawal, measured with the COWS, was an important variable, reminding clinicians that bup-nx should not be commenced prior to evidence of moderate opioid withdrawal. These findings add to the evidence that with careful procedures, bup-nx can used with few difficulties in PO-dependent patients. (Am J Addict 2014;23:343-348). © American Academy of Addiction Psychiatry.

Entities:  

Keywords:  buprenorphine; induction; prescription opioid dependence

Mesh:

Substances:

Year:  2013        PMID: 24112096      PMCID: PMC4151625          DOI: 10.1111/j.1521-0391.2013.12105.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  17 in total

1.  Comparing buprenorphine induction experience with heroin and prescription opioid users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Jacqueline Fahey; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-02-01

2.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

5.  Increasing deaths from opioid analgesics in the United States.

Authors:  Leonard J Paulozzi; Daniel S Budnitz; Yongli Xi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-09       Impact factor: 2.890

6.  Non-medical use of OxyContin Tablets in the United States.

Authors:  Karen L Sees; Michael E Di Marino; Nicole K Ruediger; Christine T Sweeney; Saul Shiffman
Journal:  J Pain Palliat Care Pharmacother       Date:  2005

Review 7.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

8.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

10.  Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Authors:  Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

View more
  4 in total

1.  Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Authors:  Petra Jacobs; Alfonso Ang; Maureen P Hillhouse; Andrew J Saxon; Suzanne Nielsen; Paul G Wakim; Barbara E Mai; Larissa J Mooney; Jennifer S Potter; Jack D Blaine
Journal:  Am J Addict       Date:  2015-09-24

2.  New depression diagnosis following prescription of codeine, hydrocodone or oxycodone.

Authors:  Jeffrey F Scherrer; Joanne Salas; Kathleen K Bucholz; F David Schneider; Thomas Burroughs; Laurel A Copeland; Mark D Sullivan; Patrick J Lustman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-03-22       Impact factor: 2.890

3.  Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review.

Authors:  Victoria D Powell; Jack M Rosenberg; Avani Yaganti; Claire Garpestad; Pooja Lagisetty; Carol Shannon; Maria J Silveira
Journal:  JAMA Netw Open       Date:  2021-09-01

4.  French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC.

Authors:  Alice Bruneau; Clarice Poirier; Mélanie Bérubé; Aline Boulanger; Céline Gélinas; Line Guénette; Anaïs Lacasse; David Lussier; Yannick Tousignant-Laflamme; M Gabrielle Pagé; Marc O Martel
Journal:  Can J Psychiatry       Date:  2022-03-15       Impact factor: 5.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.